<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Oral Cancer News &#187; erbitux</title>
	<atom:link href="http://oralcancernews.org/wp/tag/erbitux/feed/" rel="self" type="application/rss+xml" />
	<link>http://oralcancernews.org/wp</link>
	<description>The Oral Cancer Foundation News Archive</description>
	<lastBuildDate>Mon, 06 Feb 2012 22:09:34 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator>
		<item>
		<title>Third Head and Neck Indication for Erbitux</title>
		<link>http://oralcancernews.org/wp/new-indication-for-cetuximab-in-squamous-cell-carcinoma-of-the-head-and-neck/</link>
		<comments>http://oralcancernews.org/wp/new-indication-for-cetuximab-in-squamous-cell-carcinoma-of-the-head-and-neck/#comments</comments>
		<pubDate>Thu, 05 Jan 2012 18:03:40 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[colorectal cancer]]></category>
		<category><![CDATA[erbitux]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[radiation therapy]]></category>
		<category><![CDATA[squamous cell carcinoma]]></category>
		<category><![CDATA[squamous cell head and neck cancer]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=12267</guid>
		<description><![CDATA[Source: The ASCO Post, January 1, 2012, Volume 3, Issue 1, Matthew Stenger &#160; In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.Cetuximab (Erbitux) was recently approved by the FDA for use in combination with platinum-based therapy [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/new-indication-for-cetuximab-in-squamous-cell-carcinoma-of-the-head-and-neck/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDA Approves Cetuximab for Late-Stage Head and Neck Cancer</title>
		<link>http://oralcancernews.org/wp/fda-approves-cetuximab-for-late-stage-head-and-neck-cancer/</link>
		<comments>http://oralcancernews.org/wp/fda-approves-cetuximab-for-late-stage-head-and-neck-cancer/#comments</comments>
		<pubDate>Wed, 09 Nov 2011 18:05:16 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[Bristol-Myers Squibb]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[colon cancer]]></category>
		<category><![CDATA[erbitux]]></category>
		<category><![CDATA[Food and Drug Administration]]></category>
		<category><![CDATA[head and neck cancer]]></category>
		<category><![CDATA[radiation therapy]]></category>
		<category><![CDATA[squamous cell carcinoma]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=12059</guid>
		<description><![CDATA[Source: The Oncology Report The Food and Drug Administration on Nov. 7 approved cetuximab as an initial treatment of late-stage head and neck cancer in combination with chemotherapy. Cetuximab, marketed as Erbitux by Bristol-Myers Squibb, is an epidermal growth factor receptor (EGFR) antagonist, administered as an intravenous infusion. Previously, it was approved in combination with [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/fda-approves-cetuximab-for-late-stage-head-and-neck-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>US FDA approval for expanded use of Erbitux</title>
		<link>http://oralcancernews.org/wp/us-fda-approval-for-expanded-use-of-erbitux/</link>
		<comments>http://oralcancernews.org/wp/us-fda-approval-for-expanded-use-of-erbitux/#comments</comments>
		<pubDate>Wed, 09 Nov 2011 13:24:41 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[5-fluorouracil]]></category>
		<category><![CDATA[apoptosis]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[erbitux]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[infusion]]></category>
		<category><![CDATA[monoclonal antibody]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=12055</guid>
		<description><![CDATA[Source: www.pharmabiz.com Author: staff The US Food and Drug Administration (FDA) has approved Erbitux (cetuximab), in combination with platinum-based chemotherapy with 5-fluorouracil (CT), for the first-line treatment of recurrent locoregional or metastatic squamous cell carcinoma of the head and neck (SCCHN). The approval, which is based on data from the landmark EXTREME (ErbituX in first-line [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/us-fda-approval-for-expanded-use-of-erbitux/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDA Approves Cetuximab for Metastatic Head and Neck Cancer</title>
		<link>http://oralcancernews.org/wp/fda-approves-cetuximab-for-metastatic-head-and-neck-cancer/</link>
		<comments>http://oralcancernews.org/wp/fda-approves-cetuximab-for-metastatic-head-and-neck-cancer/#comments</comments>
		<pubDate>Tue, 08 Nov 2011 19:00:48 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[American Society of clinical oncology]]></category>
		<category><![CDATA[Bristol-Myers Squibb]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[erbitux]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[head and neck cancer]]></category>
		<category><![CDATA[radiation]]></category>
		<category><![CDATA[squamous cell carcinoma]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=12042</guid>
		<description><![CDATA[Source: MedScape News Today The US Food and Drug Administration (FDA) has approved cetuximab (Erbitux, Bristol-Myers Squibb ) for use in combination with chemotherapy for the treatment of metastatic head and neck cancer. Data show that when combined with cisplatin-based chemotherapy, cetuximab improved overall survival, compared with chemotherapy alone. According to the researchers, this is [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/fda-approves-cetuximab-for-metastatic-head-and-neck-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Cancer drug resistance strategy uncovered</title>
		<link>http://oralcancernews.org/wp/cancer-drug-resistance-strategy-uncovered/</link>
		<comments>http://oralcancernews.org/wp/cancer-drug-resistance-strategy-uncovered/#comments</comments>
		<pubDate>Fri, 09 Sep 2011 19:20:44 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[cancer cells]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[dana-darber cancer institute]]></category>
		<category><![CDATA[erbitux]]></category>
		<category><![CDATA[science translational medicine]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=11773</guid>
		<description><![CDATA[Source: Cancer Research UK Author: Staff &#160; Friday 9 September 2011- US scientists have identified a way in which cancer cells can become resistant to the cancer drug cetuximab (Erbitux), and suggest that treatments that are already available might be able to overcome this resistance. Researchers from the Dana-Farber Cancer Institute in Boston, US, have been studying [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/cancer-drug-resistance-strategy-uncovered/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Strategy to conquer cancer drug resistance uncovered</title>
		<link>http://oralcancernews.org/wp/strategy-to-conquer-cancer-drug-resistance-uncovered/</link>
		<comments>http://oralcancernews.org/wp/strategy-to-conquer-cancer-drug-resistance-uncovered/#comments</comments>
		<pubDate>Fri, 09 Sep 2011 12:32:14 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[antibody]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[ErbB2]]></category>
		<category><![CDATA[ErbB2 inhibitors]]></category>
		<category><![CDATA[erbitux]]></category>
		<category><![CDATA[Herceptin]]></category>
		<category><![CDATA[resistant]]></category>
		<category><![CDATA[Trastuzumab]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=11750</guid>
		<description><![CDATA[Source: info.cancerresearchuk.org Author: staff US scientists have identified a way in which cancer cells can become resistant to the cancer drug cetuximab (Erbitux), and suggest that treatments that are already available might be able to overcome this resistance. Researchers from the Dana-Farber Cancer Institute in Boston, US, have been studying why some patients only experience short-term [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/strategy-to-conquer-cancer-drug-resistance-uncovered/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Hypersensitivity Reactions to Erbitux Caused by Tick Bites.</title>
		<link>http://oralcancernews.org/wp/hypersensitivity-reactions-to-erbitux-caused-by-tick-bites/</link>
		<comments>http://oralcancernews.org/wp/hypersensitivity-reactions-to-erbitux-caused-by-tick-bites/#comments</comments>
		<pubDate>Fri, 01 Jul 2011 19:42:28 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[Bristol-Myers Squibb]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[colorectal cancer]]></category>
		<category><![CDATA[erbitux]]></category>
		<category><![CDATA[IgE antibody]]></category>
		<category><![CDATA[ImClone Systems]]></category>
		<category><![CDATA[tick bites]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=11374</guid>
		<description><![CDATA[Source: Gastroenterology &#038; Endoscopy News Hypersensitivity reactions to cetuximab (Erbitux, ImClone Systems/Bristol-Myers Squibb), a monoclonal antibody approved for use in colorectal cancer, are not caused by the drug itself but by preexisting immunoglobulin E (IgE) antibodies that may result from tick bites, researchers have found. Cetuximab, like other monoclonal antibodies, is generally associated with a [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/hypersensitivity-reactions-to-erbitux-caused-by-tick-bites/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>HPV and EGFR are hottest topics in head and neck cancer</title>
		<link>http://oralcancernews.org/wp/hpv-and-egrf-are-hottest-topics-in-head-and-neck-cancer/</link>
		<comments>http://oralcancernews.org/wp/hpv-and-egrf-are-hottest-topics-in-head-and-neck-cancer/#comments</comments>
		<pubDate>Fri, 13 May 2011 14:46:08 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[chemoradiation]]></category>
		<category><![CDATA[cisplatin]]></category>
		<category><![CDATA[EGRF inhibitors]]></category>
		<category><![CDATA[erbitux]]></category>
		<category><![CDATA[HPV]]></category>
		<category><![CDATA[human papillomavirus]]></category>
		<category><![CDATA[panitumumab]]></category>
		<category><![CDATA[prognosis]]></category>
		<category><![CDATA[radiotherapy]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=11050</guid>
		<description><![CDATA[Source: www.medscape.com Author: Zosia Chustecka The hottest topic in head and neck cancers is the role of human papillomavirus (HPV) in the disease, although there is also a lot interest in treatment with EGRF inhibitors, especially the second-generation products, according to an expert here at the European Society for Therapeutic Radiology and Oncology 11th Biennial [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/hpv-and-egrf-are-hottest-topics-in-head-and-neck-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>ASCO: Non-platinum regimen works in head, neck cancer</title>
		<link>http://oralcancernews.org/wp/asco-non-platinum-regimen-works-in-head-neck-cancer/</link>
		<comments>http://oralcancernews.org/wp/asco-non-platinum-regimen-works-in-head-neck-cancer/#comments</comments>
		<pubDate>Sun, 06 Jun 2010 14:32:19 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[alimta]]></category>
		<category><![CDATA[Avastin]]></category>
		<category><![CDATA[bevacizumab]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[erbitux]]></category>
		<category><![CDATA[monoclonal antibody]]></category>
		<category><![CDATA[pemetrexed]]></category>
		<category><![CDATA[vascular epithelial growth factor]]></category>
		<category><![CDATA[VEGF]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=8806</guid>
		<description><![CDATA[Source: www.medpagetoday.com Author: Michael Smith, North American Correspondent, MedPage Today A novel non-platinum-based regimen was efficacious in recurrent or metastatic squamous cell head and neck cancer, researchers said. The combination of pemetrexed (Alimta) and bevacizumab (Avastin) yielded a response rate of 30% in a small single-arm trial, according to Athanassios Argiris, MD, of the University [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/asco-non-platinum-regimen-works-in-head-neck-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>ASCO: Antibody improves head and neck cancer results</title>
		<link>http://oralcancernews.org/wp/asco-antibody-improves-head-and-neck-cancer-results/</link>
		<comments>http://oralcancernews.org/wp/asco-antibody-improves-head-and-neck-cancer-results/#comments</comments>
		<pubDate>Sun, 06 Jun 2010 14:24:13 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[EGFR]]></category>
		<category><![CDATA[epidermal growth factor receptor]]></category>
		<category><![CDATA[erbitux]]></category>
		<category><![CDATA[human papillomavirus]]></category>
		<category><![CDATA[monoclonal antibody]]></category>
		<category><![CDATA[nimotuzumab]]></category>
		<category><![CDATA[toxicity]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=8800</guid>
		<description><![CDATA[Source: www.medpagetoday.com Author: Michael Smith, North American Correspondent, MedPage Today A novel antibody improved outcomes for patients with advanced and inoperable squamous cell carcinoma of the head and neck, researchers reported. Combined with radiation or chemoradiation, the substance &#8212; a fully humanized monoclonal antibody dubbed nimotuzumab &#8212; significantly outperformed either modality alone in an open-label [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/asco-antibody-improves-head-and-neck-cancer-results/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Presence of rash associated with improved survival in patients receiving adjuvant Erbitux® for locally advanced head and neck cancer</title>
		<link>http://oralcancernews.org/wp/presence-of-rash-associated-with-improved-survival-in-patients-receiving-adjuvant-erbitux%c2%ae-for-locally-advanced-head-and-neck-cancer/</link>
		<comments>http://oralcancernews.org/wp/presence-of-rash-associated-with-improved-survival-in-patients-receiving-adjuvant-erbitux%c2%ae-for-locally-advanced-head-and-neck-cancer/#comments</comments>
		<pubDate>Wed, 18 Nov 2009 02:52:02 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[EGFR]]></category>
		<category><![CDATA[epithelial growth factory receptor]]></category>
		<category><![CDATA[erbitux]]></category>
		<category><![CDATA[monoclonal antibody]]></category>
		<category><![CDATA[radiotherapy]]></category>
		<category><![CDATA[rash]]></category>
		<category><![CDATA[survival]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=7393</guid>
		<description><![CDATA[Source: professional.cancerconsultants.com Author: staff A multicenter randomized trial has shown that patients with locoregionally advanced head and neck cancer receiving adjuvant Erbitux® (cetuximab) and radiotherapy who develop a rash have a better survival than patients receiving this therapy who don’t develop a rash. The details of this five-year follow-up of a Phase III randomized study [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/presence-of-rash-associated-with-improved-survival-in-patients-receiving-adjuvant-erbitux%c2%ae-for-locally-advanced-head-and-neck-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Erbitux recognized by ASCO as a 2009 major cancer advance as first SCCHN  treatment to improve survival in 30 years</title>
		<link>http://oralcancernews.org/wp/erbitux-recognized-by-asco-as-a-2009-major-cancer-advance-as-first-scchn-treatment-to-improve-survival-in-30-years/</link>
		<comments>http://oralcancernews.org/wp/erbitux-recognized-by-asco-as-a-2009-major-cancer-advance-as-first-scchn-treatment-to-improve-survival-in-30-years/#comments</comments>
		<pubDate>Tue, 17 Nov 2009 05:39:55 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[erbitux]]></category>
		<category><![CDATA[randomized trial]]></category>
		<category><![CDATA[survival]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=7372</guid>
		<description><![CDATA[Source: www.vwd.de Author: press release The American Society of Clinical Oncology (ASCO) has once again recognized Erbitux® (cetuximab) as one of the major clinical cancer advances of 2009. This year Erbitux was selected by ASCO for providing the first significant increase in survival for 30 years in the treatment of patients with first-line recurrent and/or [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/erbitux-recognized-by-asco-as-a-2009-major-cancer-advance-as-first-scchn-treatment-to-improve-survival-in-30-years/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Report highlights cancer advances</title>
		<link>http://oralcancernews.org/wp/report-highlights-cancer-advances/</link>
		<comments>http://oralcancernews.org/wp/report-highlights-cancer-advances/#comments</comments>
		<pubDate>Tue, 10 Nov 2009 15:08:06 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[erbitux]]></category>
		<category><![CDATA[gefitinib]]></category>
		<category><![CDATA[Iressa]]></category>
		<category><![CDATA[methotrexate]]></category>
		<category><![CDATA[progression-free surviva]]></category>
		<category><![CDATA[re-irradiation]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=7295</guid>
		<description><![CDATA[Source: www.medpagetoday.com Author: Charles Bankhead, Staff Writer, MedPage Today As the war on cancer enters its fifth decade, 51 studies stood out as examples of progress that occurred in the past year, as determined by the American Society of Clinical Oncology (ASCO) and reported in &#8220;Clinical Cancer Advances 2009.&#8221; Reflecting input from specialists throughout the [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/report-highlights-cancer-advances/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>At our throats</title>
		<link>http://oralcancernews.org/wp/at-our-throats/</link>
		<comments>http://oralcancernews.org/wp/at-our-throats/#comments</comments>
		<pubDate>Thu, 15 Oct 2009 20:20:48 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[alcohol]]></category>
		<category><![CDATA[cervical cancer]]></category>
		<category><![CDATA[cigarettes]]></category>
		<category><![CDATA[DNA]]></category>
		<category><![CDATA[erbitux]]></category>
		<category><![CDATA[HPV]]></category>
		<category><![CDATA[human papilloma virus]]></category>
		<category><![CDATA[radiation]]></category>
		<category><![CDATA[throat]]></category>
		<category><![CDATA[tumor]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=6982</guid>
		<description><![CDATA[Source: www.forbes.com Author: Matthew Herper Oncologist Maura Gillison was looking for patients with tonsil cancer for a clinical study several years ago. The first enlisted was a malpractice lawyer, followed by a doctor, then a scientist. She joked to a colleague that all she needed was a rear admiral. In walked a member of the [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/at-our-throats/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Erbitux® may improve treatment of squamous cell carcinoma of the esophagus</title>
		<link>http://oralcancernews.org/wp/erbitux%c2%ae-may-improve-treatment-of-squamous-cell-carcinoma-of-the-esophagus/</link>
		<comments>http://oralcancernews.org/wp/erbitux%c2%ae-may-improve-treatment-of-squamous-cell-carcinoma-of-the-esophagus/#comments</comments>
		<pubDate>Sat, 03 Oct 2009 14:26:31 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[5-FU]]></category>
		<category><![CDATA[chimeric monoclonal antibody]]></category>
		<category><![CDATA[cisplatin]]></category>
		<category><![CDATA[EGFR]]></category>
		<category><![CDATA[erbitux]]></category>
		<category><![CDATA[esophagus]]></category>
		<category><![CDATA[Platinol]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=6783</guid>
		<description><![CDATA[Source: professional.cancerconsultants.com Author: staff Researchers from Germany have reported that Erbitux® (cetuximab) improves response rate, time to disease progression, and overall survival of patients with metastatic squamous cell carcinoma receiving Platinol® (cisplatin) and 5-FU. The details of this study appeared in the October 2009 issue of Annals of Oncology.[1] Esophageal cancer is relatively common and [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/erbitux%c2%ae-may-improve-treatment-of-squamous-cell-carcinoma-of-the-esophagus/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

